



S4 Fig. Kaplan-Meier curve of groups with (dotted red) and without (blue) confirmatory bone scan (BS) for overall survival, in cases with enzalutamide-treated metastatic castration-resistant prostate cancer who showed prostate-specific antigen response ≥ 6 months.